175 related articles for article (PubMed ID: 33638195)
1. The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients.
Flores-Pérez C; Castillejos-López MJ; Chávez-Pacheco JL; Dávila-Borja VM; Flores-Pérez J; Zárate-Castañón P; Acosta-Bastidas M; Cruz-Escobar J; Torres-Espíndola LM
J Clin Pharm Ther; 2021 Jun; 46(3):633-639. PubMed ID: 33638195
[TBL] [Abstract][Full Text] [Related]
2. Sex and Age Influence on Association of
Flores-Pérez C; Flores-Pérez J; de Jesús Castillejos López M; Chávez-Pacheco JL; Tejada-Gutiérrez KM; Aquino-Gálvez A; Torres-Espíndola LM
Diagnostics (Basel); 2022 Nov; 12(11):. PubMed ID: 36428856
[TBL] [Abstract][Full Text] [Related]
3. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
4. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
5. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
6. Analysis of
Torres Espíndola LM; Rojo-Serrato D; Álvaro-Heredia A; Castillejos López MJ; de Uña-Flores A; Pérez-García M; Zapata-Tarres M; Cárdenas-Cardos R; Granados J; Chávez-Pacheco JL; Salinas-Lara C; de Arellano IT; Aquino-Gálvez A
Biomarkers; 2020 Jun; 25(4):331-340. PubMed ID: 32279544
[No Abstract] [Full Text] [Related]
7. Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation.
Fromm MF; Schwilden H; Bachmakov I; König J; Bremer F; Schüttler J
Eur J Clin Pharmacol; 2007 Dec; 63(12):1129-33. PubMed ID: 17786417
[TBL] [Abstract][Full Text] [Related]
8. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism of
Espindola LMT; López MJC; Flores AU; Espinosa LR; Granados J; Pacheco JLC; García MP; Cervantes MTR; Méndez VCB; Doño SH; Ruíz Gómez D
Arch Med Sci; 2021; 17(6):1766-1771. PubMed ID: 34900058
[TBL] [Abstract][Full Text] [Related]
10. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.
Yang G; Fu Z; Chen X; Yuan H; Yang H; Huang Y; Ouyang D; Tan Z; Tan H; Huang Z; Zhou H
Clin Ther; 2011 Dec; 33(12):2060-70. PubMed ID: 22177374
[TBL] [Abstract][Full Text] [Related]
11. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.
Yu KS; Cho JY; Jang IJ; Hong KS; Chung JY; Kim JR; Lim HS; Oh DS; Yi SY; Liu KH; Shin JG; Shin SG
Clin Pharmacol Ther; 2004 Aug; 76(2):104-12. PubMed ID: 15289787
[TBL] [Abstract][Full Text] [Related]
12. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Wong M; Balleine RL; Collins M; Liddle C; Clarke CL; Gurney H
Clin Pharmacol Ther; 2004 Jun; 75(6):529-38. PubMed ID: 15179407
[TBL] [Abstract][Full Text] [Related]
13. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
[TBL] [Abstract][Full Text] [Related]
14. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
16. Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.
Brussee JM; Vet NJ; Krekels EHJ; Valkenburg AJ; Jacqz-Aigrain E; van Gerven JMA; Swart EL; van den Anker JN; Tibboel D; de Hoog M; de Wildt SN; Knibbe CAJ
Br J Clin Pharmacol; 2018 Feb; 84(2):358-368. PubMed ID: 29072785
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of midazolam in critically ill pediatric patients.
Nahara MC; McMorrow J; Jones PR; Anglin D; Rosenberg R
Eur J Drug Metab Pharmacokinet; 2000; 25(3-4):219-21. PubMed ID: 11420893
[TBL] [Abstract][Full Text] [Related]
18. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Elens L; Nieuweboer A; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; Mathijssen RH; van Schaik RH
Pharmacogenomics; 2013 Jan; 14(2):137-49. PubMed ID: 23327575
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in CYP1A1 and CYP3A5 Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting.
Bustos ML; Zhao Y; Chen H; Caritis SN; Venkataramanan R
Pharmacotherapy; 2016 Dec; 36(12):1238-1244. PubMed ID: 27809336
[TBL] [Abstract][Full Text] [Related]
20. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
